製品番号: HY-B0227

ケトプロフェン

(別名: Ketoprofen)

9 Cited Publications

カスタマーレビュー

Based on 9 publication(s) in Google Scholar

Ketoprofen (RP-19583) is a non-steroidal anti-inflammatory agent. Ketoprofen can inhibits the activity of cyclooxygenase with IC₅₀ values of 2 nM (COX-1) and 26 nM (COX-2). which is potential in the research of inflammation, immunology, and metabolic disease such as obesity.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.95%
CAS 番号: 22071-15-4
分子式: C₁₆H₁₄O₃
分子量:254.28

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Ketoprofen 構造式

CAS 番号: 22071-15-4

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
化学情報
Publications (9)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target^[1]

COX-1

2 nM (IC₅₀, in human blood monocytes)

COX-2

26 nM (IC₅₀, in human blood monocytes)

COX アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>50 μM Compound: Ketoprofen	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32987314]
A549	IC₅₀	>50 μM Compound: Ketoprofen	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32987314]
A549	IC₅₀	>50 μM Compound: Ketoprofen	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32987314]
CHO	IC₅₀	1.3 μM Compound: Ketoprofen	TP_TRANSPORTER: inhibition of Adefovir uptake in OAT1-expressing CHO cells TP_TRANSPORTER: inhibition of Adefovir uptake in OAT1-expressing CHO cells	[PMID: 10991954]
CHO	IC₅₀	1.4 μM Compound: Ketoprofen	TP_TRANSPORTER: inhibition of 6-Carboxyfluorescein uptake in OAT1-expressing CHO cells TP_TRANSPORTER: inhibition of 6-Carboxyfluorescein uptake in OAT1-expressing CHO cells	[PMID: 10929807]
DU-145	IC₅₀	>100 μM Compound: 5; Ket	Antiproliferative activity against human DU-145 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human DU-145 cells incubated for 48 hrs by MTT assay	[PMID: 36257283]
HeLa	IC₅₀	>50 μM Compound: Ketoprofen	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32987314]
HeLa	IC₅₀	>50 μM Compound: Ketoprofen	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32987314]
HeLa	IC₅₀	>50 μM Compound: Ketoprofen	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32987314]
HT-29	IC₅₀	>100 μM Compound: 5; Ket	Antiproliferative activity against human HT-29 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells incubated for 48 hrs by MTT assay	[PMID: 36257283]
MCF7	IC₅₀	>100 μM Compound: 5; Ket	Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 36257283]
MCF7	IC₅₀	>50 μM Compound: Ketoprofen	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32987314]
MCF7	IC₅₀	>50 μM Compound: Ketoprofen	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32987314]
MCF7	IC₅₀	>50 μM Compound: Ketoprofen	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32987314]
Oocyte	IC₅₀	0.5 μM Compound: Ketoprofen	TP_TRANSPORTER: inhibition of MTX uptake in Xenopus laevis oocytes TP_TRANSPORTER: inhibition of MTX uptake in Xenopus laevis oocytes	[PMID: 11099697]
RAW264.7	IC₅₀	7.07 μM Compound: Ketoprofen	Antiinflammatory activity in LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by griess reagent based assay Antiinflammatory activity in LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by griess reagent based assay	[PMID: 38286094]
SW480	IC₅₀	>50 μM Compound: Ketoprofen	Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32987314]
SW480	IC₅₀	>50 μM Compound: Ketoprofen	Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32987314]
SW480	IC₅₀	>50 μM Compound: Ketoprofen	Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32987314]

体外実験

Ketoprofen inhibits COX in LPS-stimulated monocytes isolated from human blood, with IC₅₀ values of 2 nM (COX-1) and 26 nM (COX-2)^[1].
Ketoprofen (2.5 mg /mL, 3-24h) decreases the mRNA level of immune factors (TNFα, IL-8, SAA and COX-2) and PTGES in LPS-stimulated bovine mammary epithelial cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR^[3]

Cell Line:

LPS (0.2 μg/mL)-stimulated bovine mammary epithelial cells
Concentration:

2.5 mg /mL
Incubation Time:

3, 6, 24 h
Result:

Decreased the mRNA level of TNFα, IL-8, SAA, COX-2 and PTGES.

体内実験

Ketoprofen (Oral administration, 10 mg/kg, three times a week for 10 weeks, HFD-induced obese C57BL/6 mice) decreases in relative body weight (15.41%), the iWAT mass (approximately 41%), and leptin (58.68%) and resistin (12.88%)^[2].
Ketoprofen (50 mg/kg, LPS-treated dairy cows) lowers the increase of somatic cell count (SCC), serum albumin (SA), IgG and lactate dehydrogenase (LDH) activity in milk induced by LPS^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

HFD-induced obese C57BL/6 mice^[2]
Dosage:

10 mg/kg
Administration:

Oral administration, three times a week for 10 weeks
Result:

Decreased in relative body weight, the iWAT mass, and the level of leptin and resistin.

Animal Model:

LPS (0.2 μg/mL)-treated dairy cows ^[3]
Dosage:

50 mg/kg
Administration:

Injection (Milk samples were taken every 30 min until 6 and 9 h)
Result:

Lowered the increase of somatic cell count (SCC), serum albumin (SA), IgG and lactate dehydrogenase (LDH) activity in milk.

化学情報

CAS 番号 22071-15-4
性状 Solid
分子量 254.28
分子式 C₁₆H₁₄O₃
Color White to off-white
SMILES

O=C(C1=CC=CC=C1)C2=CC=CC(C(C(O)=O)C)=C2
別名

Ketoprofen
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (9)

All Bio/Physico-chemical Assay

Sort by:

Journal Impact Factor

Emerg Contam

2026 Feb 23.
Cell Rep

Structural basis for the reversal of human MRP4-mediated multidrug resistance by lapatinib. [Abstract]

2025 Mar 25;44(4):115466. PMID: 40138312
Biochem Pharmacol

Dual inhibition of EGR1/STAT3 transcriptional hubs suppresses macrophage-driven liver fibrosis: A multi-omics-guided drug repurposing strategy. [Abstract]

2025 Oct:240:117120. PMID: 40623460
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Eur J Pharm Sci

Biophysical and docking study on the interaction of anticancer drugs encorafenib and binimetinib with human serum albumin. [Abstract]

2023 Oct 1:189:106550. PMID: 37527692

Ketoprofen purchased from MedChemExpress. Usage Cited in: Eur J Pharm Sci. 2023 Oct 1:189:106550. [Abstract]

Binding constants for ENC and BINI to HSA derived from fluorescence quenching data obtained at 25 °C in the absence and presence of IND, Ketoprofen, HEM.
Mol Pharm

Molecular Interactions of Cobimetinib and Vemurafenib with Human Serum Albumin: a Comparative Biophysical and Computational Analysis. [Abstract]

2025 Aug 4;22(8):4969-4982. PMID: 40662409
J Neurotrauma

Improving the function of meningeal lymphatic vessels to promote brain edema absorption after TBI. [Abstract]

2023 Feb;40(3-4):383-394. PMID: 36106596
J Mol Liq

2026 May 23;457:129686.
Chemosphere

Mass-balance-model-based evaluation of sewage treatment plant contribution to residual pharmaceuticals in environmental waters. [Abstract]

2019 Jun:225:378-387. PMID: 30884299

溶剤 & 溶解度

体外:

DMSO : ≥ 100 mg/mL (393.27 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.9327 mL

19.6634 mL

39.3267 mL

5 mM

0.7865 mL

3.9327 mL

7.8653 mL

10 mM

0.3933 mL

1.9663 mL

3.9327 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.83 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (9.83 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (9.83 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (277 KB)
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Palomer A, et al. Structure-based design of cyclooxygenase-2 selectivity into ketoprofen. Bioorg Med Chem Lett. 2002 Feb 25;12(4):533-7. [Content Brief]

[2]. NamHyeon Kang Ketoprofen alleviates diet-induced obesity and promotes white fat browning in mice via the activation of COX-2 through mTORC1-p38 signaling pathway. Pflugers Arch. 2020 May;472(5):583-596. [Content Brief]

[3]. Denisa Dan, et al. Ketoprofen affects the mammary immune response in dairy cows in vivo and in vitro. J Dairy Sci. 2018 Dec;101(12):11321-11329. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.9327 mL	19.6634 mL	39.3267 mL	98.3168 mL
	5 mM	0.7865 mL	3.9327 mL	7.8653 mL	19.6634 mL
	10 mM	0.3933 mL	1.9663 mL	3.9327 mL	9.8317 mL
	15 mM	0.2622 mL	1.3109 mL	2.6218 mL	6.5545 mL
	20 mM	0.1966 mL	0.9832 mL	1.9663 mL	4.9158 mL
	25 mM	0.1573 mL	0.7865 mL	1.5731 mL	3.9327 mL
	30 mM	0.1311 mL	0.6554 mL	1.3109 mL	3.2772 mL
	40 mM	0.0983 mL	0.4916 mL	0.9832 mL	2.4579 mL
	50 mM	0.0787 mL	0.3933 mL	0.7865 mL	1.9663 mL
	60 mM	0.0655 mL	0.3277 mL	0.6554 mL	1.6386 mL
	80 mM	0.0492 mL	0.2458 mL	0.4916 mL	1.2290 mL
	100 mM	0.0393 mL	0.1966 mL	0.3933 mL	0.9832 mL

Keywords

Ketoprofen

9 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

ケトプロフェン

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Pyroptosis Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Pancreatic Cancer Compound Library

Rare Diseases Drug Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Withdrawn Drug Compound Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Highly Selective Inhibitors Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Animal Drug Library

Cardiotoxic Compound Library

MedChemExpress（MCE）の使用を引用している文献 Ketoprofen

COX アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (9)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Ketoprofen 関連分類

HY-B0227 関連分類